Particle Sciences and Microfluidics extended their collaboration with the placement of the newly-announced Microfluidics Reaction Technology (MRT) system at Particle Sciences. This revolutionary technology combines a high shear, high pressure impinging jet processor with expert process development to generate unique results in bottom-up nanoparticle creation and continuous pharmaceutical manufacturing through crystallization and chemical reactions.
According to Robert Lee, Ph.D., Vice President of Pharmaceutical Development at Particle Sciences, "Particle Sciences is extremely pleased with the potential of MRT and we have successfully used it with several client-driven projects. It definitely provides a unique approach to bottom-up nanoparticle formulation, one that lends itself to being scaled and conforming to cGMP requirements."
According to Bill Kober, Vice President of Sales, Americas, at Microfluidics, "According to a recent independent survey, approximately 80% of pharmaceutical companies are planning to invest in continuous manufacturing in 2010. MRT offers exclusive results that cannot be achieved via any other method. However, it requires more than a machine. Particle Sciences was chosen as an early site for the technology because of their deep knowledge around both pharmaceutical formulation and nanoparticle engineering. We are confident that their experienced engineers are fully trained and capable of developing processes for customers which will meet their precise and most demanding requirements."
Continuous crystallization via MRT was introduced to the United States at INTERPHEX 2010 in New York City on April 21, 2010.
Adeno-associated virus: The gene therapy revolution faces manufacturing and safety hurdles